Core Viewpoint - The company, Gilead Sciences-B (01672), has entered into a placement and subscription agreement to sell and issue shares, which will result in a significant change in shareholding structure and raise funds for clinical trials and operational needs [1][2]. Group 1: Share Placement and Subscription Details - The total number of shares to be placed is 52.4 million, representing approximately 5.44% of the company's issued share capital as of the announcement date [2]. - The subscription involves 28.82 million new shares, accounting for about 2.90% of the enlarged issued share capital post-placement and subscription [2]. - The placement price is set at HKD 16.45 per share, which is a discount of approximately 9.9% compared to the closing price of HKD 18.26 on the last trading day [2]. Group 2: Shareholding Changes - Following the completion of the placement and subscription, the selling shareholder's stake will decrease from approximately 53.38% to 49.45% of the issued share capital [2]. - The total shareholding percentage of the controlling shareholder will reduce from about 62.21% to approximately 58.03% after the issuance of the new shares [2]. Group 3: Use of Proceeds - The net proceeds from the subscription are expected to be around HKD 468 million after deducting commissions and estimated expenses [2]. - Approximately 90% of the net proceeds is intended for the development of clinical trials related to subcutaneous and oral peptide candidates for obesity [2]. - The remaining 10% of the net proceeds is suggested for working capital and other general corporate purposes [2].
歌礼制药-B拟折让约9.9%配股 净筹4.68亿港元